Close menu




July 20th, 2021 | 13:42 CEST

Siemens Healthineers, Cardiol Therapeutics, CureVac: Where there is music to be heard by the end of the year

  • Biotechnology
Photo credits: pixabay.com

Health is the highest good. Anyone who has ever experienced people having the "plug pulled" on them overnight can undoubtedly relate to this truism. Fortunately, medicine in this country is able to provide a quick remedy. A wide range of options are available for both diagnosis and therapy. In addition to laboratory analyses, imaging procedures also ensure that disease patterns can be narrowed down and, thus, treatments can be carried out in a targeted manner. Although our drugs are already powerful, new, more innovative approaches are emerging all the time. This development is also benefiting investors.

time to read: 3 minutes | Author: Nico Popp
ISIN: SIEMENS HEALTH.AG NA O.N. | DE000SHL1006 , CARDIOL THERAPEUTICS | CA14161Y2006 , CUREVAC N.V. O.N. | NL0015436031

Table of contents:


    Siemens Healthineers: Here is where Qatar comes in

    Siemens Healthineers is primarily responsible for imaging and other diagnostic equipment. The Company from the Siemens Group has been independently listed on the stock exchange since 2018. Since then, the development has been positive - the share has increased by around 50%. The trend at Siemens Healthineers is also pointing upward in the short term. Although the pandemic has caused many routine examinations to be postponed, which has also had a negative impact on Siemens Healthineers' figures, there should certainly be catch-up effects over the summer months, which are relatively quiet from an epidemiological point of view.

    With the Qatar sovereign wealth fund, Siemens Healthineers has a more than solid anchor shareholder. The emirate's investment vehicle recently participated in a capital increase that Siemens Healthineers launched to acquire cancer specialist Varian. The Company is thus realigning itself step by step and occupying promising markets. Siemens Healthineers also has its fingers in the pie when it comes to the rapid test business. With fall approaching, this business should pick up again. The stock is solid but not a high flyer.

    Cardiol Therapeutics: A matter of the heart for investors?

    An exceedingly exciting stock for any investor looking for momentum is Cardiol Therapeutics. The Company works with the active ingredient Cannabidiol (CBD) to address inflammatory heart disease in particular. In addition to the pharmacy-only CBD product Cortalex™, which has been available exclusively through the Canadian retail chain Shoppers' pharmacy portal since 2020, the Company is also researching cardiac medications. The elderly, in particular, get the extremely pure cannabidiol recommended by their doctors.

    The CardiolRx product is currently undergoing a Phase II/III FDA clinical program to evaluate the beneficial cardiovascular properties of cannabidiol in Covid-19 patients with pre-existing conditions. In addition to oral dosage forms, Cardiol is also working on subcutaneous administrations and plans to launch a study of its compound for acute myocarditis in the third quarter. This disease can sometimes affect young people or athletes who have not rested sufficiently after a simple infection. Although a diagnosed myocarditis usually heals without consequences in these patients and with sufficient rest, complications and secondary damage, such as heart failure, can also occur. At this point, the administration of CardiolRX could protect the vessels. Cardiol Therapeutics intends to investigate this effect. The stock has come back after soaring in the first quarter, also due to a capital increase that the Company recently carried out. Analysts at GBC Investment Research see the stock as promising, with a price target of CAD 15.77, and consider the stock a potential takeover target in the event of positive study results. The listing on the Nasdaq, which has already been applied for, should also bring Cardiol Therapeutics new attention. The stock is still speculative after its correction but also promising.

    CureVac: What comes after the crash?

    The CureVac share has also corrected significantly. The reason lies in unsatisfactory study results around the vaccine against Covid-19, which was less effective than comparable vaccines. To some extent, CureVac may also have been a victim of the study design and the new virus variants. Representatives of the Company still believe approval is possible. It is also undisputed among experts that CureVac has great competence around the innovative mRNA process. For this reason, the share was also considered a comeback candidate after its slump. But the comeback failed to materialize. Since the stock is more likely to move back towards the lows, there is no pressure to act here. The fantasy is gone.


    CureVac is now being viewed somewhat critically by the market, and Siemens Healthineers is more of a long-term, solid investment for investors such as Qatar's sovereign wealth fund. The shares of Cardiol Therapeutics could offer speculative potential within a narrowly defined timeframe. Its clinical trials are already underway, and it has applied for uplisting to Nasdaq. The capital increase is also through, and the share price has consolidated. The stock could have the potential for positive surprises by the end of the year.


    Conflict of interest

    Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may in the future hold shares or other financial instruments of the mentioned companies or will bet on rising or falling on rising or falling prices and therefore a conflict of interest may arise in the future. conflict of interest may arise in the future. The Relevant Persons reserve the shares or other financial instruments of the company at any time (hereinafter referred to as the company at any time (hereinafter referred to as a "Transaction"). "Transaction"). Transactions may under certain circumstances influence the respective price of the shares or other financial instruments of the of the Company.

    Furthermore, Apaton Finance GmbH reserves the right to enter into future relationships with the company or with third parties in relation to reports on the company. with regard to reports on the company, which are published within the scope of the Apaton Finance GmbH as well as in the social media, on partner sites or in e-mails, on partner sites or in e-mails. The above references to existing conflicts of interest apply apply to all types and forms of publication used by Apaton Finance GmbH uses for publications on companies.

    Risk notice

    Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and etc. on news.financial. These contents serve information for readers and does not constitute a call to action or recommendations, neither explicitly nor implicitly. implicitly, they are to be understood as an assurance of possible price be understood. The contents do not replace individual professional investment advice and do not constitute an offer to sell the share(s) offer to sell the share(s) or other financial instrument(s) in question, nor is it an nor an invitation to buy or sell such.

    The content is expressly not a financial analysis, but rather financial analysis, but rather journalistic or advertising texts. Readers or users who make investment decisions or carry out transactions on the basis decisions or transactions on the basis of the information provided here act completely at their own risk. There is no contractual relationship between between Apaton Finance GmbH and its readers or the users of its offers. users of its offers, as our information only refers to the company and not to the company, but not to the investment decision of the reader or user. or user.

    The acquisition of financial instruments entails high risks that can lead to the total loss of the capital invested. The information published by Apaton Finance GmbH and its authors are based on careful research on careful research, nevertheless no liability for financial losses financial losses or a content guarantee for topicality, correctness, adequacy and completeness of the contents offered here. contents offered here. Please also note our Terms of use.


    Der Autor

    Nico Popp

    At home in Southern Germany, the passionate stock exchange expert has been accompanying the capital markets for about twenty years. With a soft spot for smaller companies, he is constantly on the lookout for exciting investment stories.

    About the author



    Related comments:

    Commented by Fabian Lorenz on November 24th, 2022 | 12:40 CET

    New year, rising prices? BASF, BioNTech and Manuka Resources - Shares in check

    • Mining
    • Commodities
    • Biotechnology
    • chemicals

    As the stock market year 2022 draws to a close, we look ahead to 2023. New year, rising prices? That is what many stock market players are hoping for. The chances are that we will see rising indices again with the end of interest rate hikes in the coming year. Today, we look at three companies likely to attract attention in 2023. At BioNTech, the research pipeline is full to bursting, and there are numerous study results to come. BASF is attractive due to its low valuation and high dividend yield. However, analysts warn of a write-off risk. Manuka Ressources convinces with a profitable core business, and an exciting project in the field of critical raw materials could lead to a revaluation.

    Read

    Commented by Stefan Feulner on November 22nd, 2022 | 13:42 CET

    Favorable starting positions for Commerzbank, Desert Gold and BioNTech

    • Mining
    • Gold
    • Investments
    • Biotechnology

    The suspected downward pressure due to uncertainties in the economy and geopolitics has so far failed to materialize. Instead, the most important stock indices, such as DAX or Dow Jones, were able to leave their short-term downward trends and are sending signals for a further upward push. In addition to the stock market, the precious metals sector was also able to turn around. Here, in particular, entry opportunities beckon at a significantly reduced level with the chance of long-term, disproportionate price gains.

    Read

    Commented by Nico Popp on November 21st, 2022 | 12:11 CET

    Biotech - Hotter than ever: Catalyst Pharmaceuticals, BioNxt Solutions, Bayer

    • Biotechnology

    Biotechs have been providing answers to humanity's most pressing questions for years. Innovative companies are applying advanced methods to make a medical difference. The example of BioNTech is just one success story among many. While companies in the pharmaceutical sector are finding it increasingly difficult to come up with real innovations, biotechs often put all their eggs in one basket - and win. We present two biotech hopefuls and take a look at Bayer.

    Read